Fully automated method for the liquid chromatographic determination of cyproterone acetate in plasma using restricted access material for sample pre-treatment
Christiaens, B.; Chiap, Patrice; Rbeida, O.et al.
2003 • In Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 795 (1), p. 73-82
[en] A new fully automated method for the quantitative analysis of an antiandrogenic substance, cyproterone acetate (CPA), in plasma samples has been developed using on-line solid-phase extraction (SPE) prior to the determination by reversed-phase liquid chromatography (LC). The automated method was based on the use of a precolumn packed with an internal-surface reversed-phase packing material (LiChrospher RP-4 ADS) for sample clean-up coupled to LC analysis on an octadecyl stationary phase using a column-switching system. A 200-mul volume of plasma sample was injected directly on the precolumn packed with restricted access material using a mixture of water-acetonitrile (90:10, v/v) as washing liquid. The analyte was then eluted in the back-flush mode with the LC mobile phase which consisted of a mixture of phosphate buffer, pH 7.0-acetonitrile (54:46, v/v). The elution profiles of CPA and blank plasma samples on the precolumn and the time needed for analyte transfer from the precolumn to the analytical column were determined. Different compositions of washing liquid and mobile phase were tested to reduce the interference of plasma endogenous components. UV detection was achieved at 280 nm. Finally, the developed method was validated using a new approach, namely the application of the accuracy profile based on the interval confidence at 90% of the total measurement error (bias+standard deviation). The limit of quantification of cyproterone acetate in plasma was determined at 15 ng ml(-1). The validated method should be applicable to the determination of CPA in patients treated by at least 50 mg day(-1). (C) 2003 Elsevier B.V. All rights reserved.
Fully automated method for the liquid chromatographic determination of cyproterone acetate in plasma using restricted access material for sample pre-treatment
Publication date :
25 September 2003
Journal title :
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Yu Z., Westerlund D. J. Chromatogr. A. 725:1996;149.
van der Hoeven R.A.M., Hofte A.J.P., Frenay M., Irth H., Tjaden U.R., van der Greef J., Rudolphi A., Boos K.-S., Marko Varga G., Edholm L.E. J. Chromatogr. A. 762:1997;193.
Oertel R., Richter K., Gramatté T., Kirch W. J. Chromatogr. A. 797:1998;203.
Ceccato A., Boulanger B., Chiap P., Hubert Ph., Crommen J. J. Chromatogr. A. 819:1998;143.
Ceccato A., Toussaint B., Chiap P., Hubert Ph., Crommen J. Enantiomer. 4:1999;305.
Gordi T., Nielsen E., Yu Z., Westerlud D., Ashton M. J. Chromatogr. B. 742:2000;155.
Baeyens W.R.G., Van der Weken G., Haustraete J., Aboul-Enein H.Y., Corveleyn S., Remon J.P., Garcia-Campana A.M., Deprez P. J. Chromatogr. A. 871:2000;153.
Ôhman D., Carlsson B., Norlander B. J. Chromatogr. B. 753:2001;365.
Chiap P., Ceccato A., Gora R., Hubert Ph., Géczy J., Crommen J. J. Pharm. Biomed. Anal. 27:2002;447.
Guidance for Industry, Bioanalytical Method Validation. May 2001;Department of Health and Human Services Food and Drug Administration.